<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39379494</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Presence of cholestasis and its impact on survival in SARS-CoV-2 associated acute respiratory distress syndrome.</ArticleTitle><Pagination><StartPage>23377</StartPage><MedlinePgn>23377</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23377</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-73948-x</ELocationID><Abstract><AbstractText>Data on cholestasis and biliary injury in patients with COVID-19 are scarce. The primary aim of this study was to evaluate the prevalence of cholestasis and factors associated with its development and outcome in critically ill patients with COVID-19 associated acute respiratory distress syndrome (ARDS). In this retrospective exploratory study, COVID-19 patients with ARDS admitted to an intensive care unit (ICU) at the Medical University of Vienna were evaluated for the development of cholestasis defined as an alkaline phosphatase level of 1.67x upper limit of normal for at least three consecutive days. Simple and multiple logistic regression analysis was used to evaluate parameters associated with development of cholestasis and survival. Of 225 included patients 119 (53%) developed cholestasis during ICU stay. Patients with cholestasis had higher peak levels of alkaline phosphatase, gamma-glutamyl transferase, bilirubin and inflammation parameters. Factors independently associated with cholestasis were extracorporeal membrane oxygenation support, ketamine use, high levels of inflammation parameters and disease severity. Presence of cholestasis and peak ALP levels were independently associated with worse ICU and 6-month survival. Development of cholestasis is a common complication in critically ill COVID-19 patients and represents a negative prognostic marker for survival. It is associated with disease severity and specific treatment modalities of intensive care.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Schneeweiss-Gleixner</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Division of Gastroenterology and Hepatology with Intensive Care Unit 13h1, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Krenn</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, General Intensive Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petter</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Division of Gastroenterology and Hepatology with Intensive Care Unit 13h1, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haselwanter</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Division of Gastroenterology and Hepatology with Intensive Care Unit 13h1, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraft</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, General Intensive Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, General Intensive Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semmler</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Division of Gastroenterology and Hepatology with Intensive Care Unit 13h1, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartl</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Division of Gastroenterology and Hepatology with Intensive Care Unit 13h1, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halilbasic</LastName><ForeName>Emina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Division of Gastroenterology and Hepatology with Intensive Care Unit 13h1, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchtele</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine I, Intensive Care Unit 13i2, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krall</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staudinger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine I, Intensive Care Unit 13i2, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zauner</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Division of Gastroenterology and Hepatology with Intensive Care Unit 13h1, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trauner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Division of Gastroenterology and Hepatology with Intensive Care Unit 13h1, Medical University of Vienna, Vienna, Austria. michael.trauner@meduniwien.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stättermayer</LastName><ForeName>Albert Friedrich</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Division of Gastroenterology and Hepatology with Intensive Care Unit 13h1, Medical University of Vienna, Vienna, Austria. albertfriedrich.staettermayer@meduniwien.ac.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.3.1</RegistryNumber><NameOfSubstance UI="D000469">Alkaline Phosphatase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002779" MajorTopicYN="Y">Cholestasis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000469" MajorTopicYN="N">Alkaline Phosphatase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cholestasis</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">Ketamine</Keyword><Keyword MajorTopicYN="N">Liver injury</Keyword></KeywordList><CoiStatement>The authors declare no competing interests. M.T. received speaker fees from BMS, Falk Foundation, Gilead, Intercept, Ipsen, Jannsen, Madrigal, MSD and Roche; he advised for Abbvie, Agomab, Albireo, BiomX, Boehringer Ingelheim, Chemomab, Cymabay, Falk Pharma GmbH, Genfit, Gilead, Hightide, Intercept, Janssen, LoopLab, Mirum, MSD, Novartis, Phenex, Pliant, Rectify, Regulus, Siemens and Shire. He further received travel support from Abbvie, Falk, Gilead, Intercept and Jannsen and research grants from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx. He is also co-inventor of patents on the medical use of norUDCA filed by the Medical Universities of Graz and Vienna. K.K. received research grants from Apeptico, Biotest, Bayer and Alterras and travel support from Biotest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39379494</ArticleId><ArticleId IdType="pmc">PMC11461911</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-73948-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-73948-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med.8, 420–422 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta, P. et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet395, 1033–1034 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo, A. D. et al. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int.41, 20–32 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753756</ArticleId><ArticleId IdType="pubmed">33190346</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrie, J. et al. Profile of liver cholestatic biomarkers following prolonged ketamine administration in patients with COVID-19. BMC Anesthesiol.23, 44 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9902832</ArticleId><ArticleId IdType="pubmed">36750971</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot, T. et al. COVID-19 and liver disease: Mechanistic and clinical perspectives. Nat. Rev. Gastroenterol. Hepatol.18, 348–364 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7945972</ArticleId><ArticleId IdType="pubmed">33692570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni, A. V. et al. Systematic review with meta-analysis: Liver manifestations and outcomes in COVID-19. Aliment. Pharmacol. Ther.52, 584–599 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361465</ArticleId><ArticleId IdType="pubmed">32638436</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav, D. K. et al. Involvement of liver in COVID-19: Systematic review and meta-analysis. Gut70, 807–809 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7948176</ArticleId><ArticleId IdType="pubmed">32669289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-M, P. et al. Coronavirus disease (COVID-19) and the liver: A comprehensive systematic review and meta-analysis. Hepatol. Int.14, 711–722 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7335221</ArticleId><ArticleId IdType="pubmed">32623633</ArticleId></ArticleIdList></Reference><Reference><Citation>Paliogiannis, P. &amp; Zinellu, A. Bilirubin levels in patients with mild and severe Covid-19: A pooled analysis. Liver Int.40, 1787–1788 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264680</ArticleId><ArticleId IdType="pubmed">32304343</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal-Monterde, V. et al. SARS-CoV-2 infection induces a dual response in liver function tests: Association with mortality during hospitalization. Biomedicines8, 328 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7555293</ArticleId><ArticleId IdType="pubmed">32899640</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt, S. et al. Hepatobiliary long-term consequences of COVID-19: Dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients. Hepatol. Int.17, 1610–1625 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10148013</ArticleId><ArticleId IdType="pubmed">37119516</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunyady, P. et al. Secondary sclerosing cholangitis following coronavirus disease 2019 (COVID-19): A multicenter retrospective study. Clin. Infect. Dis.76, e179–e187 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278244</ArticleId><ArticleId IdType="pubmed">35809032</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards, K., Allison, M. &amp; Ghuman, S. Secondary sclerosing cholangitis in critically ill patients: A rare disease precipitated by severe SARS-CoV-2 infection. BMJ Case Rep.13 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654135</ArticleId><ArticleId IdType="pubmed">33168538</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth, N. C. et al. Post-COVID-19 cholangiopathy: A novel entity. Am. J. Gastroenterol.116, 1077–1082 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33464757</ArticleId></ArticleIdList></Reference><Reference><Citation>Durazo, F. A. et al. Post-covid-19 Cholangiopathy-A new indication for liver transplantation: A case report. Transpl. Proc.53, 1132–1137 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953456</ArticleId><ArticleId IdType="pubmed">33846012</ArticleId></ArticleIdList></Reference><Reference><Citation>Butikofer, S. et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver Int.41, 2404–2417 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242687</ArticleId><ArticleId IdType="pubmed">34018314</ArticleId></ArticleIdList></Reference><Reference><Citation>Geier, A., Fickert, P. &amp; Trauner, M. Mechanisms of disease: Mechanisms and clinical implications of cholestasis in sepsis. Nat. Clin. Pract. Gastroenterol. Hepatol.3, 574–585 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17008927</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvatits, T., Drolz, A., Trauner, M. &amp; Fuhrmann, V. Liver injury and failure in critical illness. Hepatology. 70, 2204–2215 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31215660</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt, S. et al. Secondary sclerosing cholangitis in critically ill patients: Clinical presentation, cholangiographic features, natural history, and outcome a series of 16 cases. Medicine94, e2188 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5008492</ArticleId><ArticleId IdType="pubmed">26656347</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt, S. et al. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Crit. Care19, 131 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407292</ArticleId><ArticleId IdType="pubmed">25886728</ArticleId></ArticleIdList></Reference><Reference><Citation>Beath, S. V. &amp; Kelly, D. A. Total parenteral nutrition-induced cholestasis: Prevention and management. Clin. Liver Dis.20, 159–176 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26593297</ArticleId></ArticleIdList></Reference><Reference><Citation>Madnawat, H. et al. Mechanisms of parenteral nutrition-associated liver and gut injury. Nutr. Clin. Pract.35, 63–71 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7014933</ArticleId><ArticleId IdType="pubmed">31872510</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendel-Garcia, P. D. et al. Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome. Crit. Care26, 148 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9125956</ArticleId><ArticleId IdType="pubmed">35606831</ArticleId></ArticleIdList></Reference><Reference><Citation>de Tymowski, C., Dépret, F., Dudoignon, E., Legrand, M. &amp; Mallet, V. Ketamine-induced cholangiopathy in ARDS patients. Intensive Care Med.47, 1173–1174 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8315088</ArticleId><ArticleId IdType="pubmed">34313797</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt, S., Baumann, S., Jürgensen, C., Hüter, L. &amp; Leonhardt, J. Role of intravenous ketamine in the pathogenesis of secondary sclerosing cholangitis in critically ill patients: Perpetrator or innocent bystander? Answers provided by forensic toxicology. Intensive Care Med.49, 1549–1551 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10709220</ArticleId><ArticleId IdType="pubmed">37943301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri, V. M. et al. Acute respiratory distress syndrome the berlin definition. JAMA307, 2526–2533 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumagi, T. et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am. J. Gastroenterol.105, 2186–2194 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20502446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl, L. et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. Hepatology76, 1563–1575 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9347407</ArticleId><ArticleId IdType="pubmed">35596929</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. J. et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J. Hepatol.73, 807–816 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211738</ArticleId><ArticleId IdType="pubmed">32437830</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba, T., Connors, J. M. &amp; Levy, J. H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm. Res.69, 1181–1189 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7486586</ArticleId><ArticleId IdType="pubmed">32918567</ArticleId></ArticleIdList></Reference><Reference><Citation>Lax, S. F. et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: Results from a prospective, single-center, clinicopathologic case series. Ann. Intern. Med.173, 350–361 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7249507</ArticleId><ArticleId IdType="pubmed">32422076</ArticleId></ArticleIdList></Reference><Reference><Citation>Trauner, M., Meier, P. J. &amp; Boyer, J. L. Molecular pathogenesis of cholestasis. N. Engl. J. Med.339, 1217–1227 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9780343</ArticleId></ArticleIdList></Reference><Reference><Citation>Trauner, M. &amp; Boyer, J. L. Bile salt transporters: Molecular characterization, function, and regulation. Physiol. Rev.83, 633–671 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12663868</ArticleId></ArticleIdList></Reference><Reference><Citation>Vartak, N. et al. On the mechanisms of biliary flux. Hepatology74, 3497–3512 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34164843</ArticleId></ArticleIdList></Reference><Reference><Citation>Harnisch, L. O. et al. Biomarkers of cholestasis and liver injury in the early phase of acute respiratory distress syndrome and their pathophysiological value. Diagnostics11, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8699895</ArticleId><ArticleId IdType="pubmed">34943592</ArticleId></ArticleIdList></Reference><Reference><Citation>de Tymowski, C. et al. Contributing factors and outcomes of burn-associated cholestasis. J. Hepatol.71, 563–572 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31152758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruemmele, P., Hofstaedter, F. &amp; Gelbmann, C. M. Secondary sclerosing cholangitis. Nat. Rev. Gastroenterol. Hepatol.6, 287–295 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19404269</ArticleId></ArticleIdList></Reference><Reference><Citation>Weig, T. et al. Abdominal obesity and prolonged prone positioning increase risk of developing sclerosing cholangitis in critically ill patients with influenza A-associated ARDS. Eur. J. Med. Res.17, 30 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543205</ArticleId><ArticleId IdType="pubmed">23259907</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, G. L. et al. Liver injury is common among chronic abusers of ketamine. Clin. Gastroenterol. Hepatol.12, 1759–1762e1751 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24534547</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding, Z. Y. et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J. Hepatol.74, 1295–1302 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749734</ArticleId><ArticleId IdType="pubmed">33347952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl, L. et al. Age-adjusted mortality and predictive value of liver chemistries in a viennese cohort of COVID-19 patients. Liver Int.42, 1297–1307 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115240</ArticleId><ArticleId IdType="pubmed">35412018</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan, A. et al. Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. World J. Gastroenterol.28, 570–587 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905016</ArticleId><ArticleId IdType="pubmed">35316959</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer, L., Jordan, B., Druml, W., Bauer, P. &amp; Metnitz, P. G. Incidence and prognosis of early hepatic dysfunction in critically ill patients—A prospective multicenter study. Crit. Care Med.35, 1099–1104 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17334250</ArticleId></ArticleIdList></Reference><Reference><Citation>Trauner, M. &amp; Graziadei, I. W. Review article: Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment. Pharmacol. Ther.13, 979–996 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10468672</ArticleId></ArticleIdList></Reference><Reference><Citation>Beuers, U., Trauner, M., Jansen, P. &amp; Poupon, R. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J. Hepatol.62, S25–37 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25920087</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Sulaiman, K. et al. Impact of ursodeoxycholic acid in critically ill patients with sepsis: A retrospective study. J. Pharm. Pract.36, 566–571 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37189247</ArticleId></ArticleIdList></Reference><Reference><Citation>EASL Clinical Practice Guidelines. The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol.67, 145–172 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28427765</ArticleId></ArticleIdList></Reference><Reference><Citation>EASL Clinical Practice. Guidelines on sclerosing cholangitis. J. Hepatol.77, 761–806 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35738507</ArticleId></ArticleIdList></Reference><Reference><Citation>Murillo Perez, C. F. et al. Goals of treatment for improved survival in primary biliary cholangitis: Treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am. J. Gastroenterol.115, 1066–1074 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32618657</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>